Literature DB >> 30082176

Prognostic differences in 8th edition TNM staging of esophagogastric adenocarcinoma after neoadjuvant treatment.

Leila Sisic1, Susanne Blank1, Henrik Nienhüser1, Sara Dorr1, Georg Martin Haag2, Dirk Jäger2, Thomas Bruckner3, Beat P Müller-Stich1, Katja Ott4, Markus W Büchler1, Alexis Ulrich1, Thomas Schmidt5.   

Abstract

BACKGROUND: Prognostic differences between pTN- and ypTN-categories and the prognostic accuracy of the 8th edition UICC-pTNM- and AJCC-ypTNM-staging-system for esophageal and gastric adenocarcinoma are unclear.
METHODS: We retrospectively analyzed data of 740 patients with esophagogastric adenocarcinoma, who underwent curative surgery (344 after neoadjuvant treatment [NT]) at our institution. Survival analyses were performed according to Kaplan-Meier (log-rank test). Multivariate analyses were performed using the Cox proportional hazard model.
RESULTS: Low ypT-categories did not discriminate overall survival (ypT0: reference; ypT1: HR1.0/p = 0.909; ypT2: HR0.9/p = 0.845; ypT3: HR1.5/p = 0.184; ypT4: HR2.8/p = 0.004) and no difference was found between ypN1- and ypN2-disease (ypN0: HR0.4/p < 0.001; ypN1: reference; ypN2: HR1.1/p = 0.653; ypN3: HR1.7/p = 0.014). In esophageal adenocarcinoma the UICC-TNM- and AJCC-ypTNM-staging-system was able to predict survival for patients after NT, while in gastric cancer it failed to provide sufficient prognostic information. A simplified staging system provided better stratification after NT and was an independent prognosticator for both esophageal and gastric adenocarcinoma (stage I: reference; stage II: HR2.2/p = 0.005; stage III: HR4.1/p < 0.001).
CONCLUSION: Prognostic value of ypTN-categories seems limited. After NT the current UICC/AJCC-staging-system is able to predict survival in esophageal adenocarcinoma, but needs to be reevaluated in gastric cancer patients and modified if needed. A novel simplified staging system might be more practicable for patients after NT.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Esophageal cancer; Gastric cancer; Neoadjuvant treatment; Prognosis; Staging

Mesh:

Year:  2018        PMID: 30082176     DOI: 10.1016/j.ejso.2018.06.030

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

1.  Prognostic relevance of tumor response after neoadjuvant therapy for patients with esophageal cancer.

Authors:  Elfriede Bollschweiler; Arnulf H Hölscher
Journal:  Ann Transl Med       Date:  2019-09

2.  Nomograms for Predicting Disease-Free Survival in Patients With Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction Receiving Neoadjuvant Therapy and Radical Surgery.

Authors:  Zhenjiang Guo; Honghai Guo; Yuan Tian; Ze Zhang; Qun Zhao
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

3.  Distribution of lymph node metastases in locally advanced adenocarcinomas of the esophagogastric junction (cT2-4): comparison between Siewert type I and selected Siewert type II tumors.

Authors:  Akio Sakaki; Jun Kanamori; Koshiro Ishiyama; Daisuke Kurita; Junya Oguma; Hiroyuki Daiko
Journal:  Langenbecks Arch Surg       Date:  2020-06-08       Impact factor: 3.445

4.  Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis.

Authors:  Stefano de Pascale; Paolo Parise; Michele Valmasoni; Jacopo Weindelmayer; Fabrizia Terraneo; Chiara Alessandra Cella; Simone Giacopuzzi; Andrea Cossu; Simonetta Massaron; Ugo Elmore; Stefano Merigliano; Uberto Fumagalli Romario
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

5.  Comparisons of prognosis prediction accuracy between modified and unmodified versions of 8th edition ypTNM.

Authors:  Yuequan Jiang; Yu Huang; Zhiqiang Wang; Wei Xu; Jian Xu; Fei Teng; Zhe Yin; Raja M Flores; Noriyuki Hirahara; Sofoklis Mitsos; Connor J Wakefield; Dongming Guo; Renmei Yang
Journal:  Ann Transl Med       Date:  2022-05

6.  Evaluating the eighth edition TNM staging system for esophageal cancer among patients receiving neoadjuvant therapy: A SEER study.

Authors:  Yonggang Yuan; Ge Ma; Xuelei Hu; Qingyuan Huang
Journal:  Cancer Med       Date:  2020-05-11       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.